This study will assess the role for an oral targeted medication, abrocitinib, as a new
treatment option for food allergy patients that would avoid injections. Abrocitinib, which
has successfully completed phase three trials for atopic dermatitis, could serve as a single
therapy for two conditions in many patients with multiple atopic conditions.